Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 164 for your search:
Drug:
cetuximab
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Randomized Study of Chemoradiotherapy Comprising Cisplatin, Capecitabine, and Radiotherapy With or Without Cetuximab in Patients With Carcinoma of the Esophagus
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
WCTU-SCOPE-1
, EU-20739, EUDRACT-2006-002241-37, ISRCTN47718479, CTA-17853/0202/001-0001, NCT00509561
2.
Study of MK0646 in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2007_529
, MK0646-004, NCT00614393
3.
Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCCTG-N0147
, ECOG-N0147, N0147, NCT00079274
4.
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP02-0452
, NCT00095199
5.
Phase III Randomized Study of Adjuvant Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Cetuximab in Patients With Completely Resected Stage III Colon Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 74
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
FFCD-PETACC-8
, EU-20547, EUDRACT-2005-003463-23, PETACC-8, MERCK-FFCD-PETACC-8, NCT00265811
6.
Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-C80405
, C80405, SWOG-C80405, NCT00265850
7.
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
FIRE-3
, NCT00433927
8.
Phase III Randomized Study of Chemoradiotherapy Comprising Paclitaxel, Cisplatin, and Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Esophageal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0436
, RTOG 0436, NCT00655876
9.
Phase III Randomized Study of Neoadjuvant and Adjuvant Combination Chemotherapy With Versus Without Cetuximab in Patients With Resectable Colorectal Liver Metastases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
USCTU-4351
, EPOC, USCTU-EPOC, EUDRACT-2006-003121-82, ISRCTN22944367, EU-20732, NCT00482222
10.
Phase III Randomized Study of High- Versus Standard-Dose Conformal Radiotherapy With Concurrent and Consolidation Chemotherapy Comprising Carboplatin and Paclitaxel in Patients With Newly Diagnosed, Unresectable Stage IIIA or IIIB Non-Small Cell Lung Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0617
, RTOG 0617, NCCTG-N0628, CALGB-30609, NCT00533949
11.
Phase III Randomized Study of Cetuximab With Versus Without Brivanib Alaninate in Patients With Metastatic Colorectal Carcinoma Previously Treated With Combination Chemotherapy
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CAN-NCIC-CO20
, CO20, CAN-NCIC-CA182009, NCT00640471
12.
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-Gastric Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EMR 200048-052
, NCT00678535
13.
Phase III Randomized Study of PET/CT Scan-Guided Watchful Waiting Versus Planned Neck Dissection of Locally Advanced Nodal Metastases in Patients Undergoing Chemoradiotherapy For Primary Head and Neck Squamous Cell Carcinoma
Phase:
Phase III
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
WMS-PET-NECK
, WMS-PET-NECK, ISRCTN13735240, EU-20856, MREC-07/Q1604/35, UKCRN ID: 3799, NCT00720070
14.
TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
TTCC-2007-01
, NCT00716391
15.
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-Small Cell Lung Cancer (NSCLC)
Phase:
Phase III
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EMR62240-506
, NCT00820755
16.
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
Eudract-2005-003911-63
, PEI 119/01, NCT00311857
17.
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
cpblb1-HMO-CTIL
, NCT00353717
18.
Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Gastrointestinal, Head and Neck, Non-Small Cell Lung, or Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
VU-VICC-GI-0622
, VICC-GI-0622, 6980, NCI-6980, NCT00397384
19.
Phase I/II Study of Neoadjuvant Therapy Comprising Cetuximab, Oxaliplatin, Fluorouracil, and Radiotherapy in Patients With Stage II or III Squamous Cell Carcinoma of the Esophagus
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
KRDI-TUM-OE7-432-LOR-0033-I
, EU-20658, EUDRACT-2006-001097-24, NCT00425425
20.
Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Solid Tumors or Progressive or Recurrent Stage III or IV Non-Small Cell Lung Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
UCDCC-177
, BMS-4608, BMS-CA225-261, NCT00408499
21.
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
UCIRB #14735B
, GV-001.010 (TNF-ELF), NCT00496236
22.
Phase I/II Study of Neoadjuvant Fluorouracil, Cisplatin, and Cetuximab and Concurrent Radiotherapy in Patients With Resectable Esophageal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
FFCD-0505
, FFCD-0505, EU-20756, EUDRACT-2006-004770-27, MERCK-FFCD-0505, NCT00544362
23.
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GI05-102
, NCT00522665
24.
Phase I/II Study of Pertuzumab in Combination With Cetuximab and Irinotecan Hydrochloride in Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DFCI-07070
, 07-070, 7881, NCT00551421
25.
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
07-069
, NCT00570674
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
